Objectives. ACR/EULAR Boolean remission in RA is frequently not obtained solely due to a patient global assessment (PGA) >1/10 (a condition often designated as near-remission). This study aimed to assess which domains of impact could explain an elevated PGA in near-remission patients.
Introduction
Disease remission (or at least low disease activity) is the therapeutic target for patients with RA in current treatment recommendations [1, 2] . Remission is defined according to the ACR/EULAR criteria [3] , which in the Boolean-based definition require that the 28 tender joint count (TJC28), 28 swollen joint count (SJC28), CRP (mg/dl) and patient global assessment (PGA; 010 scale) are all 41.
The condition where patients fail to reach remission solely because of PGA has been designated as near-remission [4] . These patients have no signs of significant joint inflammation since joint counts and CRP are 41, but they evaluate their disease (using PGA) as > 1/10. In published studies, 2131% of RA patients were in near-remission [46] . Following current treatment recommendations [1, 2] , this state of near-remission could justify reinforcement of immunosuppressive therapy. However, this may not be the best choice if the reason for not achieving remission is not inflammatory activity. In these cases, adjuvant therapies such as analgesics, anti-depressants or self-management programs might be more appropriate. To select the best intervention in such cases, it is essential to understand why patients without signs of significant inflammatory activity do not achieve a PGA 41.
In RA patients, PGA appears to be influenced by not only RA disease activity, but also by sociodemographic features, country/culture, psychological factors and comorbidities, with emphasis on FM [7] . However, no data are available on the meaning of PGA in the specific condition of near-remission.
The aims of this study were to assess which domains of impact may explain the elevated PGA in near-remission patients and to assess which domains of health better discriminate between disease activity states.
Methods

Study design and setting
This was an ancillary analysis of three studies of patients with established RA: baseline data from the RA Impact of Disease (RAID) elaboration database [8] , an international (12 European countries) observational study in 200809; baseline data from COMorbidities, EDucation in Rheumatoid Arthritis (COMEDRA) trial [9] , a French multicentre clinical trial in 2011; and the Coimbra RA cohort (CoimbRA), a Portuguese, cross-sectional observational study in 2015 [10] .
Participants
In all three studies consecutive adult patients were included if they had definite RA (ACR 1987 revised criteria or ACR/EULAR 2010 classification criteria) and were able to complete questionnaires. For COMEDRA, additional inclusion criteria were age <80 years, stable disease (for at least 3 months) and having no planned surgery in the 6 months following the study baseline. Written consent was obtained according to the Declaration of Helsinki for all studies, as well as approval from ethical committees, as previously reported [810] . Additional approval for this ancillary study was not required. Here, patients were analysed if they had RAID [8] and remission components available [3] .
PGA
PGA was assessed in the three studies using the same formulation [3] -considering all the ways your arthritis has affected you, how do you feel your arthritis is today?-using either a 0100 visual analogue scale or a 010 numeric rating scale (in COMEDRA). 
Remission definitions
Explanatory factors of PGA
The seven domains of the RAID score [8] were used as possible factors to explain PGA: that is, physical (pain, function and physical well-being), psychological (emotional well-being and coping/self-efficacy) and mixed domains (fatigue and sleep) [12] . Each domain is assessed by a numeric rating scale, ranging from 0 (no impact) to 10 (high impact).
Other data collection Age, gender, disease duration, current biologic agent (yes/no), HAQ, physician's global assessment and 28-joint DAS with 4 variables (DAS28-4v) were also assessed for patient's characterization.
Statistical analyses
Descriptive analyses, Student's t-test comparing disease activity states and Hedges' g for effect size (ES) were performed using SPSS Statistics version 20.0 software (IBM, Armonk, NY, USA). The ES assessed the discriminant capacity of impact domains to distinguish the disease activity states. To determine the drivers of PGA in near-remission patients, univariable (Pearson's correlation coefficient) and multivariable analyses (linear regression, backward method) were used.
Results
Patient characteristics
The evaluable population comprised 1588 patients (RAID = 348, COMEDRA = 936, CoimbRA = 304) who presented with typical established RA with long disease duration (Table 1) . Patients from COMEDRA and RAID were often treated with biologic disease-modifying drugs (74.7% and 50.0%, respectively). Disease activity was, on average, low in COMEDRA and in CoimbRA and moderate in RAID ( patients had no signs of inflammation as currently assessed, that is, they were in 3v remission (Table 1) .
In the near-remission group (n = 303), the mean PGA was considerably above the ACR/EULAR Boolean cutoff of 41 [mean 3.6 (S.D. 1.9)], with 70.3 and 43.9% of patients having a score >2 and >3, respectively (supplementary Fig. S1 , available at Rheumatology Online).
Impact domains according to disease activity states Table 2 presents disease impact domains according to remission status. In non-remission patients (n = 1090), all the disease impact domains had mean values >3.4, with coping, sleep and emotional well-being scoring lower/ better than physical domains. Conversely, in remission patients (n = 195), only fatigue (mean 1.3) and physical well-being (mean 1.1) presented means >1.
Mean values of disease impact measures were very similar for patients in near-remission and in non-remission, except (P < 0.05) for the pain, physical well-being and function domains ( Table 2 ). Mean scores of disease impact measures were markedly different between patients in remission and those in near-remission (P < 0.001 in all cases) ( Table 2 ). These two groups are brought together under the concept of 3v remission, whose values of disease impact are, as expected, between the two (Table 2 and supplementary Table S1 , available at Rheumatology Online). 
Drivers of PGA in near-remission patients
In the 303 near-remission patients, PGA presented moderate (r p = 0.47, emotional well-being) to good (r p = 0.68, pain) correlation with disease impact domains (all P < 0.001) (supplementary Table S2 , available at Rheumatology Online). In multivariable analysis, PGA was explained (R 
Main drivers of differences of impact between disease activity states
Although both remission and near-remission patients had SJC28, TJC28 and CRP 41, all mean values of impact domains were statistically higher in near-remission (supplementary Fig. S2 , available at Rheumatology Online). Within these, physical and mixed domains of impact (pain, physical well-being, function and fatigue) presented greater ESs (1.53) than psychological ones (still with a high ES >1.0). The same trend was found for comparisons between other disease activity groups, but with lower ESs (supplementary Fig. S2 , available at Rheumatology Online). Global scores (PGA and RAID) were better discriminants than individual RAID domains only when comparing remission with near-remission patients (supplementary Fig. S2 , available at Rheumatology Online).
Discussion
Several important findings emerged from this study exploring disease impact in different Boolean disease activity states. It was confirmed that ACR/EULAR Booleanbased remission is very stringent (12.3% of all patients). Near-remission, that is, failing to reach remission solely due to PGA, was at least as frequent as and up to four times more frequent than remission. Because of the influence of PGA, the percentage of patients classified as in remission was reduced from 31.4% (3v remission) to 12.3%. The scores of the diverse domains of impact in near-remission patients were similar to those for patients in non-remission and PGA was high in these patients (mean 3.6). Pain, physical well-being, function and fatigue were the impact domains that better differentiated remission from near-remission states. These results were confirmed by multivariable analyses, supporting the conclusion that high PGA in near-remission patients is driven by physical factors (which might represent subclinical inflammatory activity) and does not especially reflect psychological aspects, including anxiety or distress, or FM, contradicting common beliefs [7, 13] .
This study has strengths and weaknesses. A weakness may be the relatively low percentage of patients in remission, which might limit the power. Using different multicultural cohorts imposes some cautions in the interpretation of results. However, it allowed for a larger sample and permitted us to analyse multicultural differences in PGA and its impact on the classification of remission. How PGA is measured and its relatively unclear cut-offs and formulations are another issue [7] . Using the same formulation in the three studies strengthened this pooled analysis. Some relevant comorbidities such as FM, depression and radiological damage were not assessed, although psychological distress and function were assessed through the RAID questionnaire [8] . Further studies might explore their influence on PGA. Finally, other measures of quality of life than the RAID would have strengthened this study.
One recent study explored PGA determinants in different levels of disease activity [14] , but using tertiles of DAS28 instead of ACR/EULAR remission criteria [3] and the small sample rendered assessment of remission not feasible and a DAS28 <4.2 was adopted. The ratio of near-remission vs remission rates was variable between studies, from 1:1 to 4:1. Possible reasons to explain this difference could include culture, which may affect PROs [15] . Other reasons could be differences in the provision of patient education, psychological support and patient expectations between countries. Near-remission rate differences could also be affected by the reliability of joint counts [16] . SJC and TJC may miss subclinical inflammation in joints [17] , and totally ignore inflammation in other structures, such as tenosynovitis, which patients can still perceive and value. The use of US [18] or sensitive CRP measurement (which reflects inflammatory activity when routine CRP is 41) [19] rather than current methods should be further explored, especially in patients in near-remission.
As expected, patients in remission had a low disease impact. Fatigue was, among this group of patients and also among all, the domain with the highest mean score, underlining its importance in the impact of RA, even in patients in remission [20] .
The findings reported herein have important implications for clinical practice. Patients in near-remission presented high levels of symptoms, with mean scores 3.5. Although a higher cut-off for PGA in the definition of remission would certainly increase the number of remissions, it would not make clinical sense in patients whose high PGA is not related to residual inflammation but to structural damage or an unrelated comorbidity such as OA, depression or FM. Such patients would require adjunctive tailored interventions (e.g. patient education, physiotherapy, analgesics, antidepressants or cognitive behavioural therapy) and not the reinforcement of disease-modifying medication recommended to those not achieving remission. Another important issue is when to stop or taper immunosuppression-is the target then remission or near-remission? The present results support the idea that PGA poses problems when used in the combined definition of remission. Perhaps having two separate definitions of remission: one for the purposes of defining the target of immunosuppressive therapy (excluding PGA) and another that is patient based would make sense.
The impact of disease from the patient's perspective should continue to be taken very seriously, but this would be better served by an instrument that allows identification of the specific cause of persistent impact and thus guide adjunctive therapy. The RAID [8] , taking its individual dimensions separately, may well be a good solution to this need.
